Edwards Lifesciences (EW) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
Edwards Lifesciences's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Edwards Lifesciences's ROA in the third quarter of 2026? Edwards Lifesciences Corporation achieved a return on average assets (ROA) of 7.45 % in its third quarter of 2026, which is below Edwards Lifesciences's average return on assets, which stands at 16.64%.
ROA has improved compared to 7.41% in the second quarter of 2026, due to net income growth.
However, within the Healthcare sector 122 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 758, from total ROA ranking in the second quarter of 2026 at 895.
Breaking Barriers: All-Female TAVI Trial Demonstrates Exceptional Outcomes Using Edwards Valves In a landmark achievement for both medical science and gender-specific healthcare, the first all-female TAVI (transcatheter aortic valve implantation) trial revealed outstanding outcomes for women receiving Edwards Lifesciences Corporation valves. This pivotal study not only underscores the efficacy of Edwards valves but also shines a spotlight on the necessity and benefits of gender-specific medical research.The trial, which involved an all-female cohort, found that women who underwent TAVI procedures using Edwards valves experienced remarkable improvements in both cardiac function and overall quality of life. TAVI, a minimally invasive procedure that replaces a diseased aortic valve, has been a game-changer in cardiology, particularly for patients who are at high surgical risk. Historically, clinical trials in cardiology have either underrepresented women or failed to analyze gender-specific outcomes, making this study a significant step forward in addressing these gaps.
Comment on EW's ROA in the fiscal year ending 2025
In the fiscal year 2025 Edwards Lifesciences's ROA decreased compared to previous year to 7.65 %, due to deterioration of net income -74.35 % to $1,069.40 million, from $4,169.70 million a year ago, as EW's assets were $13,975.80 million.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
